Literature DB >> 24145988

New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma.

Tushar Patel1.   

Abstract

Intrahepatic cholangiocarcinoma is an aggressive malignancy and is one of the most devastating cancers of the gastrointestinal tract. The molecular mechanisms contributing to the pathogenesis of these cancers are not well understood. The recognition and distinction of these cancers from other tumors such as perihilar or extrahepatic distal cholangiocarcinoma and hepatocellular carcinoma are important in defining the pathogenesis. New insights into molecular mechanisms contributing to disease pathogenesis are emerging from recent epidemiological, genome-wide profiling and laboratory based studies. These have contributed to an improved understanding of risk factors, genetic mutations and pathophysiological mechanisms that are associated with these tumors. The contribution of well-established risk factors such as biliary tract inflammation and key signaling pathways involved in intrahepatic cholangiocarcinoma are being further defined. These new insights have several important implications for both molecular diagnosis and therapy of these cancers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24145988      PMCID: PMC3944910          DOI: 10.1007/s00535-013-0894-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  56 in total

Review 1.  Bile duct cysts in adults.

Authors:  K Söreide; H Körner; J Havnen; J A Söreide
Journal:  Br J Surg       Date:  2004-12       Impact factor: 6.939

2.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

3.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Authors:  Daniela Sia; Yujin Hoshida; Augusto Villanueva; Sasan Roayaie; Joana Ferrer; Barbara Tabak; Judit Peix; Manel Sole; Victoria Tovar; Clara Alsinet; Helena Cornella; Brandy Klotzle; Jian-Bing Fan; Christian Cotsoglou; Swan N Thung; Josep Fuster; Samuel Waxman; Juan Carlos Garcia-Valdecasas; Jordi Bruix; Myron E Schwartz; Rameen Beroukhim; Vincenzo Mazzaferro; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-04       Impact factor: 22.682

4.  Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.

Authors:  Hiroaki Sugiyama; Kenichiro Onuki; Kazunori Ishige; Nobue Baba; Tetsuya Ueda; Sachiko Matsuda; Kaoru Takeuchi; Masafumi Onodera; Yasuni Nakanuma; Masayuki Yamato; Masakazu Yamamoto; Ichinosuke Hyodo; Junichi Shoda
Journal:  J Gastroenterol       Date:  2011-02-18       Impact factor: 7.527

Review 5.  Intrahepatic cholangiocarcinoma: macroscopic type and stage classification.

Authors:  Susumu Yamasaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003

6.  Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.

Authors:  Yan-Ming Zhou; Zheng-Feng Yin; Jia-Mei Yang; Bin Li; Wen-Yu Shao; Feng Xu; Yu-Lan Wang; Dian-Qi Li
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

7.  Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.

Authors:  Hashem B El-Serag; Eric A Engels; Ola Landgren; Elizabeth Chiao; Louise Henderson; Harshinie C Amaratunge; Thomas P Giordano
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

8.  Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial.

Authors:  T Takada; Y Nimura; H Katoh; T Nagakawa; T Nakayama; T Matsushiro; H Amano; K Wada
Journal:  Hepatogastroenterology       Date:  1998 Nov-Dec

Review 9.  Classification, diagnosis, and management of cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Clin Gastroenterol Hepatol       Date:  2012-09-13       Impact factor: 11.382

10.  Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.

Authors:  J W Valle; H Wasan; P Johnson; E Jones; L Dixon; R Swindell; S Baka; A Maraveyas; P Corrie; S Falk; S Gollins; F Lofts; L Evans; T Meyer; A Anthoney; T Iveson; M Highley; R Osborne; J Bridgewater
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more
  20 in total

1.  Detection of early-stage extrahepatic cholangiocarcinoma in patients with biliary strictures by soluble B7-H4 in the bile.

Authors:  Wenbo Ke; Li Zeng; Yunbi Hu; Sisi Chen; Min Tian; Qinggang Hu
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

2.  MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer.

Authors:  Valeria Canu; Andrea Sacconi; Laura Lorenzon; Francesca Biagioni; Federica Lo Sardo; Maria Grazia Diodoro; Paola Muti; Alfredo Garofalo; Sabrina Strano; Antonietta D'Errico; Gian Luca Grazi; Mario Cioce; Giovanni Blandino
Journal:  Oncotarget       Date:  2017-05-02

3.  LRRK2 Is Associated with Recurrence-Free Survival in Intrahepatic Cholangiocarcinoma and Downregulation of LRRK2 Suppresses Tumor Progress In Vitro.

Authors:  Shen Gu; Jun Chen; Qun Zhou; Minghao Yan; Jian He; Xiaodong Han; Yudong Qiu
Journal:  Dig Dis Sci       Date:  2019-09-05       Impact factor: 3.199

4.  Genomics in the Early Detection of Cholangiocarcinoma.

Authors:  Emmanuel Thomas
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-06

Review 5.  Cholangiocarcinoma: from molecular biology to treatment.

Authors:  Ana F Brito; Ana M Abrantes; João C Encarnação; José G Tralhão; Maria F Botelho
Journal:  Med Oncol       Date:  2015-10-01       Impact factor: 3.064

6.  MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN.

Authors:  Li-Juan Wang; Chen-Chen He; Xin Sui; Meng-Jiao Cai; Cong-Ya Zhou; Jin-Lu Ma; Lei Wu; Hao Wang; Su-Xia Han; Qing Zhu
Journal:  Oncotarget       Date:  2015-03-20

Review 7.  Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies.

Authors:  Giovanni Brandi; Andrea Farioli; Annalisa Astolfi; Guido Biasco; Simona Tavolari
Journal:  Oncotarget       Date:  2015-06-20

Review 8.  What are the precursor and early lesions of peripheral intrahepatic cholangiocarcinoma?

Authors:  Yasuni Nakanuma; Akemi Tsutsui; Xiang Shan Ren; Kenichi Harada; Yasunori Sato; Motoko Sasaki
Journal:  Int J Hepatol       Date:  2014-04-22

9.  Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma.

Authors:  Kyung-Hun Lee; Kyoung-Bun Lee; Tae-Yong Kim; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh; Ja-June Jang; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2015-10-16       Impact factor: 4.430

10.  High Expression of ITGA3 Promotes Proliferation and Cell Cycle Progression and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma.

Authors:  Yu Huang; Yang Kong; Lufei Zhang; Tianyu He; Xiaohu Zhou; Yingcai Yan; Linshi Zhang; Dongkai Zhou; Sinan Lu; Jiarong Zhou; Lin Zhou; Haiyang Xie; Shusen Zheng; Weilin Wang
Journal:  Biomed Res Int       Date:  2018-02-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.